- Home
- GMRE vs BCYC Comparison
GMRE vs BCYC Comparison
Compare GMRE & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMRE
- BCYC
- Stock Information
- Founded
- GMRE 2011
- BCYC 2009
- Country
- GMRE United States
- BCYC United Kingdom
- Employees
- GMRE N/A
- BCYC N/A
- Industry
- GMRE Real Estate Investment Trusts
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- GMRE Real Estate
- BCYC Health Care
- Exchange
- GMRE Nasdaq
- BCYC Nasdaq
- Market Cap
- GMRE 450.4M
- BCYC 492.1M
- IPO Year
- GMRE N/A
- BCYC 2019
- Fundamental
- Price
- GMRE $30.86
- BCYC $7.96
- Analyst Decision
- GMRE Buy
- BCYC Buy
- Analyst Count
- GMRE 3
- BCYC 11
- Target Price
- GMRE $51.88
- BCYC $22.91
- AVG Volume (30 Days)
- GMRE 255.0K
- BCYC 303.4K
- Earning Date
- GMRE 11-05-2025
- BCYC 10-30-2025
- Dividend Yield
- GMRE 9.67%
- BCYC N/A
- EPS Growth
- GMRE N/A
- BCYC N/A
- EPS
- GMRE 0.34
- BCYC N/A
- Revenue
- GMRE $141,896,000.00
- BCYC $19,281,000.00
- Revenue This Year
- GMRE $7.21
- BCYC N/A
- Revenue Next Year
- GMRE $2.80
- BCYC N/A
- P/E Ratio
- GMRE $92.42
- BCYC N/A
- Revenue Growth
- GMRE 2.95
- BCYC N/A
- 52 Week Low
- GMRE $30.09
- BCYC $6.10
- 52 Week High
- GMRE $48.13
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- GMRE 73.17
- BCYC 58.20
- Support Level
- GMRE $32.16
- BCYC $7.40
- Resistance Level
- GMRE $33.48
- BCYC $8.69
- Average True Range (ATR)
- GMRE 1.24
- BCYC 0.38
- MACD
- GMRE 0.21
- BCYC 0.11
- Stochastic Oscillator
- GMRE 72.65
- BCYC 62.23
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.